THE NEED FOR HBV GENOTYPING: A COST-EFFICIENT APPROACH

Rev Med Chir Soc Med Nat Iasi. 2015 Oct-Dec;119(4):982-7.

Abstract

The outcome of chronic HBV infection is variable; approximately one half of individuals transition to an inactive carrier state, 30% progress to cirrhosis, and the remainder to chronic hepatitis. Ten different HBV genotypes and many subtypes have been identified with distinct geographical distributions. Over the years, a lot of studies presented the efficiency of different genotyping methods; for this reason we aimed to present a cost efficient genotyping diagnosis algorithm of CHB infected patients, especially useful to identify those at risk of disease progression and determine optimal anti-viral therapy as useful instrument for physicians.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / economics
  • Antiviral Agents / therapeutic use
  • Cost-Benefit Analysis
  • DNA, Viral / genetics*
  • Disease Progression
  • Genotype*
  • Genotyping Techniques / economics*
  • Hepatitis B Surface Antigens / genetics*
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis B, Chronic / economics*
  • Hepatitis B, Chronic / genetics*
  • Humans
  • Interferons / economics
  • Interferons / therapeutic use
  • Romania
  • Treatment Outcome

Substances

  • Antiviral Agents
  • DNA, Viral
  • Hepatitis B Surface Antigens
  • Interferons